Stem Cell Transplantation
An Introduction to Stem Cell Transplantation
Haematopoietic stem cell transplantation (SCT) is a lifesaving procedure for patients with a range of haematological malignancies and genetic diseases associated with abnormal haematopoiesis and function. Challenges include expanding the donor number by haploidentical (half-matched) HCT, reduction of transplant-related toxicity and reduction or delay in post-transplant relapse.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Stem Cell Transplantation Content
Christopher Hourigan, EHA 2019 – Allogenic Transplantation for AML
We are joined by Christopher Hourigan at the EHA annual meeting to discuss his presentation on the impact of conditioning intensity of allogenic transplantation for acute myeloid leukaemia with genomic evidence of residual disease. Questions 1. What different conditioning regimens are typically used before allogeneic haematopoietic stem cell transplantation (HSCT)? (0:05) 2. What factors affect […]
Bmi1 – A Path to Targeting Cancer Stem Cells
European Oncology & Haematology, 2017;13(2):147–51 DOI: https://doi.org/10.17925/EOH.2017.13.02.147
Since the discovery of the Polycomb group (PcG) gene family in Drosophila as repressors of homeotic (HOX) genes, PcG proteins have been implicated in a range of processes from chromosome X inactivation to stem cell plasticity and differentiation. PcG proteins execute their function through transcriptional repression of the promoter region of a target gene. Although […]
Plasmacytic Post-transplant Lymphoproliferative Disorder – Case Report
European Oncology & Haematology, 2017;13(1):80–2 DOI: https://doi.org/10.17925/EOH.2017.13.01.80
Post-transplant lymphoproliferative disorder (PTLD) is a severe complication of haematopoietic stem cell transplantation (HSCT). Most of the PTLDs originate from B-cells. Overall, 60–80% of PTLDs are associated with Epstein-Barr virus (EBV); this can vary depending on PTLD type and time of onset after HSCT.1,2 The majority of the general population is infected by EBV during their […]
Targeting Cancer Stem Cells—A Renewed Therapeutic Paradigm
Oncology & Hematology Review, 2017;13(1):45–55 DOI: https://doi.org/10.17925/OHR.2017.13.01.45
Despite substantial advances in cancer diagnosis and treatment, the long-term survival rate for many cancer patients remains dismal.1 More than 90% of cancer-related mortality is ascribed to disease resurgence months or years after adjuvant therapy, either in the form of local recurrence or in the form of metastatic spread, which are typically refractory to existing […]
EBMT patient registry
The EBMT announces the half million patients registered in its Registry and launches a handcrafted explainer video. With this video, viewers will get to understand the importance of the Registry and how it has contributed to the advances in blood stem cell transplants.
Rupert Handgretinger – The haploidentical/TCRab approach to stem cell transplantation – Part 2
To go back to the first part of the interview, click here Rupert Handgretinger discusses the haploidentical/TCRab approach to stem cell transplantation and the major challenges of stem cell manufacturing when conducting a multicenter clinical trial. Dr Rupert Handgretinger has received honoraria from Miltenyi Biotec. The filming of this video was supported by Miltenyi […]
Rupert Handgretinger – The haploidentical/TCRab approach to stem cell transplantation – Part 1
To watch the second part of the interview, click here Rupert Handgretinger discusses the design and outcomes of the haploidentical/TCRab clinical trial on stem cell transplantation, and the advantages in terms of GVHD prevention compared to other approaches. Dr Rupert Handgretinger has received honoraria from Miltenyi Biotec. The filming of this video was supported […]
EBMT 2017: Register now for the 43rd Annual Meeting of the EBMT
The Annual Meeting of the European Society for Blood and Marrow Transplantation is the premiere event for blood and marrow transplantation and cell therapy. Take a look at what the conference has to offer and what’s coming up at the 2017 meeting. EBMT 2017 runs from 26-29 March 2017, in Marseille, France. This video has […]
ASH 2016 Mohamad Mohty Interview Part 2
Dr Mohamad Mohty discusses consolidation and maintenance therapy in multiple myeloma and whether these therapies can replace autologous stem cell transplantation (ASCT). FILMED AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING 2016, SAN DIEGO, CALIFORNIA, US
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!